Future development of novel selective steroids that retain beneficial anti-inflammatory effects but lack adverse effects on antimicrobial immunity and mucin production could be more effective for treatment/prevention of COPD exacerbations and thus be of greater benefit in clinical practice. The gene discussed is MUC5AC; the disease is chronic obstructive pulmonary disease.